Cargando…

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis

BACKGROUND: Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of randomized controlled trials (RCTs) of exon skipping drugs h...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu-Motohashi, Yuko, Murakami, Terumi, Kimura, En, Komaki, Hirofumi, Watanabe, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003096/
https://www.ncbi.nlm.nih.gov/pubmed/29907124
http://dx.doi.org/10.1186/s13023-018-0834-2